Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Astria Therapeutics Inc (ATXS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Astria Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
9.500 +0.320    +3.49%
01/05 - Closed. Currency in USD ( Disclaimer )
After Hours
9.200
-0.300
-3.158%
0:58:18 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 2,712,154
  • Bid/Ask: 7.030 / 11.450
  • Day's Range: 9.020 - 9.830
Astria Therapeutics 9.500 +0.320 +3.49%

Astria Therapeutics Inc Company Profile

 
Get an in-depth profile of Astria Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

45

Equity Type

ORD

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Contact Information

Address 75 State Street Suite 1400
Boston, 02109
United States
Phone 617 349 1971
Fax 617 273 2637

Top Executives

Name Age Since Title
Kenneth M. Bate 74 2014 Independent Chairman of the Board
Jill C. Milne 55 2008 Co-Founder, CEO, President & Director
Jonathan Violin 48 2021 Independent Director
Hugh M. Cole 58 2019 Independent Director
Frederick Peter Callori 55 2021 Independent Director
Gregory Anthony Lapointe 64 2019 Independent Director
Jay D. Horton - - Member of Scientific Advisory Board
Joanne T. Beck 61 2019 Independent Director
Johannes Jacob Pieter Kastelein 69 - Member of Scientific Advisory Board
Steven E. Shoelson - - Member of Scientific Advisory Board
Roger Ulrich - - Member of Scientific Advisory Board
Michael Jirousek 64 2008 Member of Scientific Advisory Board
Sekar Kathiresan 51 - Member of Scientific Advisory Board
Edward M. Scolnick 82 - Member of Scientific Advisory Board
Michael D. Kishbauch 74 2016 Independent Director
Arthur H. Rubenstein 86 - Member of Scientific Advisory Board
Sunil Agarwal 54 2024 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ATXS Comments

Write your thoughts about Astria Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email